<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Tuberculosis - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Tuberculosis</span>
        </nav>

        <header class="page-header">
            <h1>Tuberculosis</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Infectious Disease</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0018076" target="_blank">
                        MONDO:0018076
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Bacterial Infection</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Tuberculosis is a contagious bacterial infection caused by Mycobacterium tuberculosis that primarily affects the lungs but can involve any organ. It spreads through airborne transmission and can exist in latent or active forms, with the active form causing characteristic symptoms including chronic cough, fever, night sweats, and weight loss.
            </p>
            
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">10</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Trials</div>
            </div>
        </div>

        <!-- Classifications -->
        

        <!-- Subtypes -->
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Phagocytosis</div>
                
                <div class="item-desc">Mycobacterium tuberculosis is engulfed by alveolar macrophages but resists destruction, leading to granuloma formation.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Macrophage
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000235" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        T Cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000084" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        neutrophil
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000775" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        dendritic cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000451" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        type I interferon signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0034138" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        autophagy
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006914" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        phagosome maturation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0090382" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/14745511" target="_blank">PMID:14745511</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The immune response to Mycobacterium tuberculosis (Mtb) infection is the formation of multicellular lesions, or granolomas, in the lung of the individual"</div>
                
                
                <div class="evidence-explanation">This reference supports the claim that Mycobacterium tuberculosis infection leads to granuloma formation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30306257" target="_blank">PMID:30306257</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Phagocytosis refers to the process of internalization and degradation of particulate material... One microbe that is particularly successful at surviving within macrophages is the pathogen Mycobacterium tuberculosis, which can efficiently manipulate the macrophage at several levels, including..."</div>
                
                
                <div class="evidence-explanation">This reference supports the specific involvement of macrophages and the resistance of Mycobacterium tuberculosis to degradation within phagocytes.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/2425678" target="_blank">PMID:2425678</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The process of granuloma formation in the lung is mediated by an intimate interaction between macrophages and T cells, and this interaction provides the appropriate environment for granuloma formation and the development of fibrosis."</div>
                
                
                <div class="evidence-explanation">While this reference supports the role of macrophages and T cells in granuloma formation, it does not address the specific mechanisms by which Mycobacterium tuberculosis resists destruction.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Granuloma Formation</div>
                
                <div class="item-desc">Immune cells form a granuloma to contain the infection, but sometimes the bacteria can break out, causing active TB.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Macrophage
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000235" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        T Cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000084" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        lipid metabolic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006629" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        cholesterol transport
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030301" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        inflammatory response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/14745511" target="_blank">PMID:14745511</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The immune response to Mycobacterium tuberculosis (Mtb) infection is the formation of multicellular lesions, or granolomas, in the lung of the individual."</div>
                
                
                <div class="evidence-explanation">The reference describes the formation of granulomas in the lung as part of the immune response to Mtb infection, which aligns with the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28577054" target="_blank">PMID:28577054</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The typical composition is a center of macrophages/histiocytes with lymphocytes at the border."</div>
                
                
                <div class="evidence-explanation">The reference indicates the involvement of macrophages and T cells (lymphocytes) in granuloma formation, which supports the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36920308" target="_blank">PMID:36920308</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"granulomas are pathologically diverse, their tissue-wide heterogeneity has not been spatially resolved at the single-cell level in human tissues."</div>
                
                
                <div class="evidence-explanation">The reference discusses the diversity of granulomas in the lung and their formation in response to TB, which supports the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Neutrophil Activation and NETosis</div>
                
                <div class="item-desc">Type I interferon-linked neutrophil programs drive NET formation contributing to tissue pathology, caseating necrosis, and vascular occlusion in progressive TB.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neutrophil
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000775" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        neutrophil degranulation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0043312" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        neutrophil extracellular trap formation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0062025" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Tissue Damage</div>
                
                <div class="item-desc">Active TB can cause cavitation and destruction of lung tissue.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32482293" target="_blank">PMID:32482293</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Cavitation is a dangerous consequence of pulmonary tuberculosis associated with poor outcomes, treatment relapse, higher transmission rates, and development of drug resistance."</div>
                
                
                <div class="evidence-explanation">The reference explicitly mentions cavitation as a severe consequence of pulmonary tuberculosis, which aligns with the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27245780" target="_blank">PMID:27245780</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Human TB lesions are severely hypoxic and M.tb drives HIF-1alpha accumulation, synergistically increasing collagenase activity which will lead to lung destruction and cavitation."</div>
                
                
                <div class="evidence-explanation">This reference provides evidence that TB lesions result in hypoxia and enzymatic activity that contributes to the destruction of lung tissue and cavitation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16136463" target="_blank">PMID:16136463</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Pulmonary cavitation with cough-generated aerosol is the principle means of spread, and lung remodeling (healed cavitation, fibrosis, and bronchiectasis) is a major cause of lung disability."</div>
                
                
                <div class="evidence-explanation">This reference discusses the relationship between TB, cavitation, and lung tissue remodeling, underscoring the statement that active TB causes cavitation and tissue damage.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">⬡</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph TD
    Tissue_Damage[&#34;Tissue Damage&#34;]
    Granuloma_Formation[&#34;Granuloma Formation&#34;]
    Phagocytosis[&#34;Phagocytosis&#34;]
    Neutrophil_Activation_and_NETosis[&#34;Neutrophil Activation and NETosis&#34;]

    Phagocytosis --&gt; Granuloma_Formation
    Granuloma_Formation --&gt; Tissue_Damage
    Neutrophil_Activation_and_NETosis --&gt; Tissue_Damage

    style Tissue_Damage fill:#dbeafe
    style Granuloma_Formation fill:#dbeafe
    style Phagocytosis fill:#dbeafe
    style Neutrophil_Activation_and_NETosis fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">10</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Chronic Cough
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0034315" target="_blank">
                            HP:0034315
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29196066" target="_blank">PMID:29196066</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Cough is common in pulmonary TB and other chronic respiratory infections."</div>
                
                
                <div class="evidence-explanation">While cough is indeed a common symptom of pulmonary TB, the statement specifically categorizes chronic cough as very frequent, which is partially supported but not explicitly confirmed by the literature.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16131501" target="_blank">PMID:16131501</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A persistent, non-remitting cough was reported in 15/16 (93.8%) children with tuberculosis."</div>
                
                
                <div class="evidence-explanation">This strongly supports the statement as it shows a high prevalence of a persistent chronic cough in children diagnosed with tuberculosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35710915" target="_blank">PMID:35710915</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Initial microbiologic burdens and radiographic features also varied, including the presence of cavities and bilateral infiltration, which reflect TB-related severity."</div>
                
                
                <div class="evidence-explanation">The study identifies chronic cough as a significant symptomatic characteristic among the different TB phenotypes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Fever
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001945" target="_blank">
                            HP:0001945
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11120618" target="_blank">PMID:11120618</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We describe three patients with recurrent fever thought to be due to tuberculosis, and review the 14 previously reported cases who fulfil the criteria of recurrent fever for at least 1 month&#39;s duration"</div>
                
                
                <div class="evidence-explanation">The literature indicates that fever is a frequent symptom associated with tuberculosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31641790" target="_blank">PMID:31641790</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Tuberculosis is a bacterial infectious disease that is usually transmitted by inhalation of droplets containing the bacteria."</div>
                
                
                <div class="evidence-explanation">While this reference does affirm that tuberculosis causes systemic issues, it does not directly specify fever as a frequent phenotype.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/18173876" target="_blank">PMID:18173876</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"SETTING: The diagnosis of tuberculosis (TB) may be rejected in the absence of symptoms such as fever, sweats or weight loss."</div>
                
                
                <div class="evidence-explanation">This reference notes the association of fever with tuberculosis but also highlights cases where fever may be absent, hence only partially supporting the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Night Sweats
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0030166" target="_blank">
                            HP:0030166
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31599243" target="_blank">PMID:31599243</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Cough, night sweat, fever, anorexia were significant presenting features."</div>
                
                
                <div class="evidence-explanation">The study documents night sweats as a significant symptom in TB patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12643362" target="_blank">PMID:12643362</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Tuberculosis and lymphoma are diseases in which night sweats are a dominant symptom, but these are infrequently found to be the cause of night sweats in modern practice."</div>
                
                
                <div class="evidence-explanation">While night sweats are a notable symptom of TB, the reference suggests that in modern practice, they are less frequently the cause of night sweats compared to other conditions.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21813327" target="_blank">PMID:21813327</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"During therapy, fever, sweats, and dyspnea decreased most rapidly, with near resolution by the end of therapy."</div>
                
                
                <div class="evidence-explanation">The data supports the presence of night sweats as a frequent symptom in TB, with sweats reducing significantly during therapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Weight Loss
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001824" target="_blank">
                            HP:0001824
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Also known as consumption historically.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36451280" target="_blank">PMID:36451280</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Tuberculosis (TB) is well-known for causing wasting. Patients on treatment gain weight and weight loss is associated with unfavorable treatment outcomes."</div>
                
                
                <div class="evidence-explanation">This supports the statement that weight loss is a frequently observed systemic phenotype associated with tuberculosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38736083" target="_blank">PMID:38736083</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Esophageal TB most commonly presents with dysphagia, odynophagia, retrosternal pain, and systemic symptoms like decreased appetite, loss of weight, and low-grade fever as associated or other presentations."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by indicating that weight loss is a common systemic symptom of esophageal tuberculosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23531875" target="_blank">PMID:23531875</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"CBA/J mice may model these events, as sick mice share features with TB patients, including weight loss..."</div>
                
                
                <div class="evidence-explanation">Although the study is on mice, it draws parallels with human TB patients, reinforcing that weight loss is a frequently observed phenotype.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hemoptysis
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Hematologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002105" target="_blank">
                            HP:0002105
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Coughing up blood.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12816036" target="_blank">PMID:12816036</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The most common causes of hemoptysis are tuberculosis, lung carcinoma, bronchiectasis but idiopathic forms are frequent."</div>
                
                
                <div class="evidence-explanation">The text states that tuberculosis is one of the most common causes of hemoptysis, supporting the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Chest Pain
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0100749" target="_blank">
                            HP:0100749
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Often described as pleuritic chest pain</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17508531" target="_blank">PMID:17508531</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Pleuritic chest pain is a common presenting symptom and has many causes, which range from life-threatening to benign, self-limited conditions."</div>
                
                
                <div class="evidence-explanation">The reference mentions pleuritic chest pain as a common symptom, but it does not specifically state that it is frequently associated with tuberculosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27499981" target="_blank">PMID:27499981</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"TPE usually presents as an acute illness with fever, cough and pleuritic chest pain."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement as it explicitly mentions that tuberculous pleural effusion (a form of extrapulmonary tuberculosis) commonly presents with pleuritic chest pain.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30762202" target="_blank">PMID:30762202</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Chest is the commonest site of involvement by tuberculosis (TB) in children; lungs being the most frequently affected region, followed by nodes, pleura and chest wall."</div>
                
                
                <div class="evidence-explanation">While this reference does not directly state chest pain, it supports the involvement of the chest in tuberculosis, which can be associated with pleuritic chest pain.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Dyspnea
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002094" target="_blank">
                            HP:0002094
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Shortness of breath</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15623010" target="_blank">PMID:15623010</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Symptoms of pulmonary TB are a cough with or without sputum production lasting at least three weeks, chest pain, hemoptysis, fever, night sweats, weight loss, lack of appetite, chills and weakness."</div>
                
                
                <div class="evidence-explanation">The abstract mentions that dyspnea (shortness of breath) is a symptom of pulmonary tuberculosis, which supports the statement that dyspnea is occasionally associated with tuberculosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29900887" target="_blank">PMID:29900887</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Lung function impairment is known to occur after pulmonary TB irrespective of duration of treatment and outcome of disease."</div>
                
                
                <div class="evidence-explanation">This reference indicates that lung function issues, including dyspnea, can persist even after successful treatment of tuberculosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Fatigue
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0012378" target="_blank">
                            HP:0012378
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33645194" target="_blank">PMID:33645194</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Sarcoidosis is a systemic granulomatous disorder of unknown cause that occurs in both men and women of all races. It typically presents in patients after 20 years of age. Sarcoidosis most frequently involves the lung, but up to 30 percent of patients present with extra-thoracic manifestations...."</div>
                
                
                <div class="evidence-explanation">The abstract mentions that tuberculosis can be misdiagnosed as sarcoidosis due to similar symptoms, including fatigue, indicating that fatigue can be a systemic symptom of tuberculosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35189895" target="_blank">PMID:35189895</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Patients with chronic fatigue syndrome and post-tuberculosis experience similar symptoms. Furthermore, chronic fatigue syndrome and tuberculosis share similar plasma immunosignatures."</div>
                
                
                <div class="evidence-explanation">The study indicates that tuberculosis can lead to symptoms similar to chronic fatigue syndrome, supporting the statement that fatigue can be a systemic symptom of tuberculosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Back Pain
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Musculoskeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0003418" target="_blank">
                            HP:0003418
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">May indicate spinal tuberculosis (Pott&#39;s disease)</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16882280" target="_blank">PMID:16882280</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The findings of this study indicate that TB is a common cause of LBP that is liable to be overlooked in the differential diagnosis of LBP."</div>
                
                
                <div class="evidence-explanation">The study indicates that tuberculosis is a common cause of low back pain (LBP), supporting the statement that back pain may indicate spinal tuberculosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29358061" target="_blank">PMID:29358061</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We present a case report of a military veteran presenting with neck pain and initially diagnosed with cervical disc disease. The patient&#39;s pain progressed to the point of developing paresthesias in his bilateral upper extremities. Eventually, cervical spine radiographs were obtained that..."</div>
                
                
                <div class="evidence-explanation">This case report supports the statement that back pain may indicate spinal tuberculosis, as it describes a patient whose neck pain was eventually diagnosed as spinal tuberculosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19845697" target="_blank">PMID:19845697</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In TB spondylitis, the lumbar (22.7%) and thoracic (50%) vertebrae were the most commonly involved sites."</div>
                
                
                <div class="evidence-explanation">This study supports the statement by indicating that the lumbar and thoracic vertebrae are commonly involved in TB spondylitis, which can manifest as back pain.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Lymphadenopathy
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Lymphatic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002716" target="_blank">
                            HP:0002716
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Swollen lymph nodes, especially in the neck</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30513392" target="_blank">PMID:30513392</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"TB can affect most organs in the head and neck region, such as the lymph nodes, larynx, middle ear, oral cavity and pharynx. In particular, as for cervical tuberculosis lymphadenopathy, a predominant involvement of the posterior triangle, supraclavicular, and internal jugular group of nodes..."</div>
                
                
                <div class="evidence-explanation">The literature supports that tuberculosis can cause lymphadenopathy, specifically in the neck region, but it does not provide a clear indication of frequency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38317037" target="_blank">PMID:38317037</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Other major causes of lymphadenopathy were metastatic tumor deposits, reactive lymphoid hyperplasia, and tuberculous lymphadenitis."</div>
                
                
                <div class="evidence-explanation">The literature indicates that tuberculous lymphadenitis is one of the major causes of lymphadenopathy, but it does not specify how frequently this occurs.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37743370" target="_blank">PMID:37743370</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Close to half of patients with enlarged lymph nodes were positive for M. tuberculosis by the GeneXpert method in the study area."</div>
                
                
                <div class="evidence-explanation">The study shows a significant prevalence of TB lymphadenitis among patients with enlarged lymph nodes, but it does not provide a frequency classification such as &#39;occasional&#39;.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TREM2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Foamy macrophage formation and Mtb persistence)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    APOE
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Lipid metabolism in TB-infected macrophages)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NPC2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Lysosomal cholesterol handling)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PLIN2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Lipid droplet marker in foamy macrophages)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    LIPA
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Lysosomal lipid catabolism)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TBK1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Type I interferon signaling pathway)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IRF3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Interferon regulatory transcription factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Isoniazid
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">First-line antibiotic for TB treatment.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33106268" target="_blank">PMID:33106268</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Isoniazid (INH), one of the first-line drugs used for the treatment of tuberculosis, is a prodrug which is activated by the intracellular KatG enzyme of Mycobacterium tuberculosis."</div>
                
                
                <div class="evidence-explanation">The description of Isoniazid as a first-line antibiotic for TB treatment and its activation by the KatG enzyme is supported. This aligns with the provided mechanism of prodrug activation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12164478" target="_blank">PMID:12164478</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The drugs shown to inhibit mycolic acid biosynthesis are isoniazid, ethionamide, isoxyl, thiolactomycin, and triclosan."</div>
                
                
                <div class="evidence-explanation">The inhibition of mycolic acid biosynthesis by Isoniazid aligns with the described mechanism of action in the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Rifampicin
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Bactericidal antibiotic used for TB treatment.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11290327" target="_blank">PMID:11290327</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Rifampicin (Rif) is one of the most potent and broad spectrum antibiotics against bacterial pathogens and is a key component of anti-tuberculosis therapy, stemming from its inhibition of the bacterial RNA polymerase (RNAP)."</div>
                
                
                <div class="evidence-explanation">This reference explains that Rifampicin is a key component of anti-tuberculosis therapy due to its inhibition of bacterial RNA polymerase.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27553018" target="_blank">PMID:27553018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"For the treatment of TB, administration of multiple antibiotics such as isoniazid, rifampicin, pyrazinamide, and ethambutol is required for a long period of time to kill bacteria."</div>
                
                
                <div class="evidence-explanation">This reference confirms that rifampicin is used for the treatment of TB.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34400805" target="_blank">PMID:34400805</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Rifamycins exhibit bactericidal activity against many Gram-positive and Gram-negative bacteria by inhibiting RNA polymerase (RNAP)."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by confirming that Rifamycins, including rifampicin, exhibit bactericidal activity by inhibiting RNA polymerase.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Ethambutol
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Bacteriostatic antibiotic used for TB treatment.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16209089" target="_blank">PMID:16209089</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Ethambutol (EMB), the first line drug in the treatment of tuberculosis, is an inhibitor of the biosynthesis of the cell wall compound - arabinogalactan."</div>
                
                
                <div class="evidence-explanation">The literature states that ethambutol interferes with the biosynthesis of arabinogalactan, supporting the mechanism described in the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/9949810" target="_blank">PMID:9949810</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Isoniazid is the most widely used antituberculosis drug."</div>
                
                
                <div class="evidence-explanation">The statement specifies ethambutol as a bacteriostatic antibiotic used for TB treatment, whereas this reference talks about isoniazid. It is partially relevant since ethambutol is also an antituberculosis drug, but this reference does not fully address ethambutol&#39;s function.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37289062" target="_blank">PMID:37289062</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In combination with TB antibiotics, wollamide B1 synergistically enhances the activity of several antibiotics... and wollamide B1 did not compromise the antimycobacterial activity of the isoniazid/rifampicin/ethambutol combination."</div>
                
                
                <div class="evidence-explanation">This reference confirms that ethambutol is used in combination with other antitubercular drugs, aligning with the notes in the statement about preventing the emergence of drug resistance.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Directly Observed Therapy (DOT)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Health worker observes and records patients taking their medication to ensure adherence.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17943789" target="_blank">PMID:17943789</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Directly observed therapy (DOT), which involves people directly observing patients taking their antituberculous drugs."</div>
                
                
                <div class="evidence-explanation">The abstract clearly states that DOT involves someone directly observing patients taking their antituberculous drugs to ensure adherence.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29461901" target="_blank">PMID:29461901</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The World Health Organization (WHO) propagates Directly Observed Therapy Short-course (DOTS) as an effective way to stop the spread of TB in communities with a high burden."</div>
                
                
                <div class="evidence-explanation">The abstract indicates that DOTS is endorsed by WHO as a method to ensure patients adhere to TB treatment.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28410705" target="_blank">PMID:28410705</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A flexible, patient centered approach were a family member can act as the DOT provider with guidance from a trained health worker was evolved as the most acceptable and comfortable mode of treatment to majority of the TB patients"</div>
                
                
                <div class="evidence-explanation">The abstract reinforces the involvement of a health worker in observing DOT, even if it&#39;s flexible to involve family members.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Latent TB Treatment
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Isoniazid or rifapentine used to prevent latent TB from becoming active.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29910114" target="_blank">PMID:29910114</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The 3-month isoniazid-rifapentine regimen is as safe and effective as other recommended latent tuberculosis infection regimens and achieves significantly higher treatment completion rates."</div>
                
                
                <div class="evidence-explanation">This source supports the statement mentioning that a regimen of isoniazid and rifapentine is used for latent TB infection.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19496388" target="_blank">PMID:19496388</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The treatment of choice for LTBI is isoniazid for nine months."</div>
                
                
                <div class="evidence-explanation">This source supports the use of isoniazid for the prevention of latent tuberculosis infection (LTBI).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32551948" target="_blank">PMID:32551948</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The World Health Organization recommends the use of isoniazid (INH) alone or in combination with rifapentine to treat latent tuberculosis infections."</div>
                
                
                <div class="evidence-explanation">This supports the statement by specifying that WHO recommends isoniazid and rifapentine for the treatment of latent tuberculosis infections.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Host-Directed Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Adjunctive strategies to enhance autophagy, modulate inflammasome activity, or reprogram macrophage lipid metabolism alongside standard antibiotics.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Tuberculin Skin Test (TST)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25440529" target="_blank">PMID:25440529</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Worldwide, tuberculin skin tests (TSTs) commonly give false positive results for those who had been given the Bacillus-Calmette-Guerin vaccine such as is routinely administered in Turkey."</div>
                
                
                <div class="evidence-explanation">While mentioning the possibility of false positives due to BCG vaccination, the reference acknowledges that positive TST results primarily indicate TB infection.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Interferon-Gamma Release Assay (IGRA)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28220979" target="_blank">PMID:28220979</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"TB-IGRA results were in positive proportion to the lymphocytes, CD4(+) T cells and CD4(+) CD28(+) T cells, whereas negative to the Treg cells."</div>
                
                
                <div class="evidence-explanation">This study discusses the positive TB-IGRA test results in patients infected with tuberculosis, supporting the statement that a positive IGRA indicates TB infection.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26018533" target="_blank">PMID:26018533</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Recently, two new diagnostic tests have been introduced; these two new tests can detect TB infection in patients by challenging peripheral blood cells with specific TB proteins."</div>
                
                
                <div class="evidence-explanation">The abstract confirms that the Interferon-Gamma Release Assay (IGRA) is a blood test used to detect TB infection.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33276277" target="_blank">PMID:33276277</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Accurate and early detection of M. bovis infection in buffaloes is important for controlling transmission. Assays that detect cell-mediated immune responses to M. bovis in buffaloes have been developed although these often display suboptimal sensitivity or specificity."</div>
                
                
                <div class="evidence-explanation">This study discusses IGRA as a diagnostic tool for detecting TB infections, supporting the claim.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #f5f3ff; color: #a855f7;">🔬</div>
                <h2 class="card-title">Clinical Trials</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box clinical-trial-box">
                <div class="item-name">
                    NCT03568383
                    
                    <span class="tag tag-phase">PHASE_III</span>
                    
                    
                </div>
                
                <div class="item-desc">Open-label randomized prophylaxis study comparing delamanid versus isoniazid for preventing active tuberculosis among high-risk household contacts of adults with multidrug-resistant TB over 96 weeks of follow-up.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT03568383" target="_blank">clinicaltrials:NCT03568383</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among high-risk household contacts (HHCs) of adults with..."</div>
                
                
                <div class="evidence-explanation">This trial evaluates delamanid as preventive therapy for household contacts of MDR-TB patients, directly relevant to tuberculosis control strategies.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Tuberculosis
description: Tuberculosis is a contagious bacterial infection caused by Mycobacterium
  tuberculosis that primarily affects the lungs but can involve any organ. It spreads
  through airborne transmission and can exist in latent or active forms, with the
  active form causing characteristic symptoms including chronic cough, fever, night
  sweats, and weight loss.
category: Infectious Disease
parents:
- Bacterial Infection
infectious_agent:
- name: Mycobacterium tuberculosis
  infectious_agent_term:
    preferred_term: Mycobacterium tuberculosis
    term:
      id: NCBITaxon:1773
      label: Mycobacterium tuberculosis
  description: A bacterium that primarily affects the lungs but can affect other organs.
  evidence:
  - reference: PMID:27784885
    supports: SUPPORT
    snippet: Tuberculosis (TB) is an airborne infectious disease caused by organisms
      of the Mycobacterium tuberculosis complex. Although primarily a pulmonary pathogen,
      M. tuberculosis can cause disease in almost any part of the body.
    explanation: The statement correctly identifies Mycobacterium tuberculosis as
      a bacterium that primarily affects the lungs but can affect other organs.
  - reference: PMID:37057936
    supports: SUPPORT
    snippet: Mycobacterium tuberculosis belongs to the group of mycobacteria, most
      of which can cause a delayed hypersensitivity reaction in the body and is a
      bacterium that causes tuberculosis.
    explanation: This reference confirms that Mycobacterium tuberculosis is a bacterium
      that causes TB and can affect the lungs.
  - reference: PMID:33306806
    supports: SUPPORT
    snippet: Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis
      (MTB). It spreads from one person to the another through the air while coughing,
      spitting, speaking or sneezing. TB most commonly affects lungs but it can affect
      any organ system.
    explanation: This reference supports the claim that tuberculosis, caused by Mycobacterium
      tuberculosis, primarily affects the lungs but can also affect other organ systems.
transmission:
- name: Airborne Transmission
  description: Spread through the air when individuals with active TB cough, sneeze,
    or speak.
  evidence:
  - reference: PMID:6338584
    supports: SUPPORT
    snippet: Subsequent evidence has indicated that direct contact is unimportant,
      although close proximity facilitates airborne transmission.
    explanation: The literature confirms airborne transmission of tuberculosis and
      mentions that direct contact is unimportant in its spread.
  - reference: PMID:20529335
    supports: SUPPORT
    snippet: Tuberculosis is a highly infectious disease that is spread from person
      to person by infected aerosols emitted by patients with respiratory forms of
      the disease.
    explanation: This excerpt explicitly states that TB is spread by aerosols generated
      by respiratory activities.
  - reference: PMID:26198113
    supports: SUPPORT
    snippet: Tuberculosis (TB) is an airborne disease caused by Mycobacterium tuberculosis
      (MTB) that usually affects the lungs leading to severe coughing, fever, and
      chest pains.
    explanation: This statement confirms that TB is an airborne disease.
  - reference: PMID:34639431
    supports: SUPPORT
    snippet: Airborne MTB was detected in 2.2% of samples (13/572), and 97.8% were
      negative.
    explanation: The study provides empirical evidence of the presence of Mycobacterium
      tuberculosis in the air, supporting airborne transmission.
  - reference: PMID:30307321
    supports: SUPPORT
    snippet: Tuberculosis (TB) is a contagious and airborne infectious disease caused
      by the pathogen Mycobacterium tuberculosis (Mtb).
    explanation: This reference also reaffirms that TB is an airborne infectious disease.
prevalence:
- population: Global
  percentage: 0.1
  evidence:
  - reference: PMID:35577247
    supports: REFUTE
    snippet: Globally, the prevalence rate of LTBI decreased from 30.66% in 1990 to
      23.67% in 2019, with an AAPC of -0.9%.
    explanation: The prevalence rate of latent tuberculosis infection (LTBI) is much
      higher than 0.1% globally, at approximately 23.67% as of 2019.
  - reference: PMID:30454918
    supports: REFUTE
    snippet: An estimated 1.7 billion (23%) of the world&#39;s population is infected
      with Mycobacterium tuberculosis leading to more than 10 million new tuberculosis
      (TB) cases each year.
    explanation: The prevalence of tuberculosis infection is around 23%, much higher
      than the 0.1% suggested in the statement.
  - reference: PMID:33296141
    supports: NO_EVIDENCE
    snippet: Tuberculosis (TB) is a widespread disease that crosses the human and
      animal health boundaries, with infection being reported in wildlife, from temperate
      and subtropical to arctic regions.
    explanation: This source discusses the prevalence of TB in wildlife but doesn’t
      provide specific global prevalence rates in humans.
  - reference: PMID:32324750
    supports: NO_EVIDENCE
    snippet: A TB prevalence of 74.1 (95% CI 48.3-99.3) per 100,000 adult population
      for smear positive TB and 119.3 (95% CI 78.8-159.9) per 100,000 adult population
      for bacteriological confirmed MTB was estimated for Rwanda.
    explanation: This source provides data specific to Rwanda not global prevalence
      rates.
  - reference: PMID:23219235
    supports: NO_EVIDENCE
    snippet: Tuberculosis (TB) epidemiology is characterized by significant differences
      in prevalence between men and women worldwide, with cases among men exceeding
      those found in women by a ratio of 2:1 in some regions.
    explanation: This source addresses sex differences in TB prevalence but not the
      global prevalence rate.
progression:
- phase: Latent
  duration: Variable
  notes: Non-contagious stage where the bacteria are present in the body but inactive.
  evidence:
  - reference: PMID:30021818
    supports: PARTIAL
    snippet: Human TB infection, from latent infection to active disease, exists within
      a continuous spectrum of metabolic bacterial activity and antagonistic immunological
      responses.
    explanation: This reference supports the concept of variable progression within
      the latent phase but does not explicitly refer to the duration being variable
      or confirm the non-contagious stage where bacteria are inactive.
  - reference: PMID:23460007
    supports: SUPPORT
    snippet: Latent tuberculosis infection (LTBI) refers to a circumstance in which
      viable Mycobacterium tuberculosis (MTB) bacilli are present in an individual
      but symptoms and signs of active disease are lacking, and the bacilli are relatively
      inactive metabolically.
    explanation: The reference directly supports the statement that during the latent
      phase, tuberculosis is in a non-contagious stage where the bacteria are present
      but inactive.
- phase: Active
  duration: Variable
  notes: Contagious stage where symptoms appear and the bacteria can be spread to
    others.
  evidence:
  - reference: PMID:30021818
    supports: SUPPORT
    snippet: Recent research has clearly demonstrated that human TB infection, from
      latent infection to active disease, exists within a continuous spectrum of metabolic
      bacterial activity and antagonistic immunological responses.
    explanation: This indicates the variable duration of progression from latent to
      active TB, supporting the statement.
  - reference: PMID:37094782
    supports: SUPPORT
    snippet: &#39;In this cohort, children and adolescents diagnosed with TB experienced
      symptoms for a median of 85 days (interquartile range: 30, 231 days) prior to
      treatment initiation.&#39;
    explanation: The variable duration of symptom onset supports the statement.
  - reference: PMID:35704248
    supports: SUPPORT
    snippet: The system considers demographic structure coupling with the continuous
      development of disease stage, which is crucial for studying how aging affects
      tuberculosis dynamics and disease progression.
    explanation: This implies that TB progression has a variable duration depending
      on individual factors like age.
pathophysiology:
- name: Phagocytosis
  description: Mycobacterium tuberculosis is engulfed by alveolar macrophages but
    resists destruction, leading to granuloma formation.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: T Cell
    term:
      id: CL:0000084
      label: T cell
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  - preferred_term: dendritic cell
    term:
      id: CL:0000451
      label: dendritic cell
  biological_processes:
  - preferred_term: type I interferon signaling pathway
    term:
      id: GO:0034138
      label: type I interferon signaling pathway
  - preferred_term: autophagy
    term:
      id: GO:0006914
      label: autophagy
  - preferred_term: phagosome maturation
    term:
      id: GO:0090382
      label: phagosome maturation
  downstream:
  - target: Granuloma Formation
    description: Infected macrophages differentiate into foamy macrophages which form the cellular core of TB granulomas.
  evidence:
  - reference: PMID:14745511
    supports: SUPPORT
    snippet: The immune response to Mycobacterium tuberculosis (Mtb) infection is
      the formation of multicellular lesions, or granolomas, in the lung of the individual
    explanation: This reference supports the claim that Mycobacterium tuberculosis
      infection leads to granuloma formation.
  - reference: PMID:30306257
    supports: SUPPORT
    snippet: Phagocytosis refers to the process of internalization and degradation
      of particulate material... One microbe that is particularly successful at surviving
      within macrophages is the pathogen Mycobacterium tuberculosis, which can efficiently
      manipulate the macrophage at several levels, including modulation of the phagocytic
      pathway as well as interfering with a number of immune activation pathways that
      normally would lead to eradication of the internalized bacilli.
    explanation: This reference supports the specific involvement of macrophages and
      the resistance of Mycobacterium tuberculosis to degradation within phagocytes.
  - reference: PMID:2425678
    supports: PARTIAL
    snippet: The process of granuloma formation in the lung is mediated by an intimate
      interaction between macrophages and T cells, and this interaction provides the
      appropriate environment for granuloma formation and the development of fibrosis.
    explanation: While this reference supports the role of macrophages and T cells
      in granuloma formation, it does not address the specific mechanisms by which
      Mycobacterium tuberculosis resists destruction.
  - reference: PMID:25607549
    supports: PARTIAL
    snippet: Upon invading host cells by phagocytosis, M. tuberculosis can replicate
      within infected cells by arresting the maturation of the phagosome whose function
      is to target the pathogen for elimination.
    explanation: This reference partially supports the claim by highlighting that
      M. tuberculosis avoids destruction within host cells, though it does not explicitly
      mention granuloma formation.
- name: Granuloma Formation
  description: Immune cells form a granuloma to contain the infection, but sometimes
    the bacteria can break out, causing active TB.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: T Cell
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: lipid metabolic process
    term:
      id: GO:0006629
      label: lipid metabolic process
  - preferred_term: cholesterol transport
    term:
      id: GO:0030301
      label: cholesterol transport
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Tissue Damage
    description: Granuloma necrosis leads to cavitation and destruction of lung parenchyma.
    evidence:
    - reference: PMID:26758178
      supports: SUPPORT
      snippet: Adult or postprimary tuberculosis (TB) accounts for most TB cases. Its
        hallmark is pulmonary cavitation, which occurs as a result of necrosis in
        the lung in individuals with tuberculous pneumonia.
      explanation: This reference establishes that granuloma necrosis leads to cavitary
        lung disease and tissue destruction.
  locations:
  - preferred_term: Lung
    term:
      id: UBERON:0002048
      label: lung
  evidence:
  - reference: PMID:14745511
    supports: SUPPORT
    snippet: The immune response to Mycobacterium tuberculosis (Mtb) infection is
      the formation of multicellular lesions, or granolomas, in the lung of the individual.
    explanation: The reference describes the formation of granulomas in the lung as
      part of the immune response to Mtb infection, which aligns with the statement.
  - reference: PMID:28577054
    supports: SUPPORT
    snippet: The typical composition is a center of macrophages/histiocytes with lymphocytes
      at the border.
    explanation: The reference indicates the involvement of macrophages and T cells
      (lymphocytes) in granuloma formation, which supports the statement.
  - reference: PMID:36920308
    supports: SUPPORT
    snippet: granulomas are pathologically diverse, their tissue-wide heterogeneity
      has not been spatially resolved at the single-cell level in human tissues.
    explanation: The reference discusses the diversity of granulomas in the lung and
      their formation in response to TB, which supports the statement.
  - reference: PMID:25319335
    supports: PARTIAL
    snippet: Mycobacterium tuberculosis, the bacterium that causes tuberculosis (TB),
      is an intracellular pathogen of mononuclear phagocytes.
    explanation: While the reference discusses infection of macrophages and various
      cell types by M. tuberculosis, it doesn&#39;t mention T cells and granuloma formation
      specifically.
  - reference: PMID:33720848
    supports: SUPPORT
    snippet: Granuloma formation is the pathologic hallmark of tuberculosis (TB).
    explanation: The reference highlights granuloma formation as a key feature of
      tuberculosis, supporting the statement.
- name: Neutrophil Activation and NETosis
  description: Type I interferon-linked neutrophil programs drive NET formation contributing to tissue pathology, caseating necrosis, and vascular occlusion in progressive TB.
  cell_types:
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: neutrophil degranulation
    term:
      id: GO:0043312
      label: neutrophil degranulation
  - preferred_term: neutrophil extracellular trap formation
    term:
      id: GO:0062025
      label: neutrophil extracellular trap formation
  locations:
  - preferred_term: Lung
    term:
      id: UBERON:0002048
      label: lung
  downstream:
  - target: Tissue Damage
    description: NETs contribute to immunopathology, tissue injury, and relapse risk in TB.
- name: Tissue Damage
  locations:
  - preferred_term: Lung
    term:
      id: UBERON:0002048
      label: lung
  description: Active TB can cause cavitation and destruction of lung tissue.
  evidence:
  - reference: PMID:32482293
    supports: SUPPORT
    snippet: Cavitation is a dangerous consequence of pulmonary tuberculosis associated
      with poor outcomes, treatment relapse, higher transmission rates, and development
      of drug resistance.
    explanation: The reference explicitly mentions cavitation as a severe consequence
      of pulmonary tuberculosis, which aligns with the statement.
  - reference: PMID:27245780
    supports: SUPPORT
    snippet: Human TB lesions are severely hypoxic and M.tb drives HIF-1alpha accumulation,
      synergistically increasing collagenase activity which will lead to lung destruction
      and cavitation.
    explanation: This reference provides evidence that TB lesions result in hypoxia
      and enzymatic activity that contributes to the destruction of lung tissue and
      cavitation.
  - reference: PMID:16136463
    supports: SUPPORT
    snippet: Pulmonary cavitation with cough-generated aerosol is the principle means
      of spread, and lung remodeling (healed cavitation, fibrosis, and bronchiectasis)
      is a major cause of lung disability.
    explanation: This reference discusses the relationship between TB, cavitation,
      and lung tissue remodeling, underscoring the statement that active TB causes
      cavitation and tissue damage.
  - reference: PMID:25361920
    supports: SUPPORT
    snippet: After many months, the affected lung suddenly undergoes caseation necrosis
      with vanishingly few MTB. The necrotic tissue fragments to produce a cavity
      or hardens to develop fibrocaseous disease.
    explanation: This reference explains the process of caseation necrosis leading
      to cavity formation in the lung, which supports the statement regarding active
      TB causing cavitation and tissue destruction.
genetic:
- name: TREM2
  association: Foamy macrophage formation and Mtb persistence
  notes: TREM2-positive macrophages are enriched in alveoli, colocalize with lipid droplets and Mtb antigens, and form permissive niches for bacterial persistence. Mycolic acids and PDIM induce TREM2 expression.
- name: APOE
  association: Lipid metabolism in TB-infected macrophages
  notes: Part of TREM2-positive foamy macrophage signature; mediates lipid trafficking that supports intracellular bacterial niche.
- name: NPC2
  association: Lysosomal cholesterol handling
  notes: Upregulated in foamy macrophages; altered cholesterol transport contributes to lipid droplet accumulation and permissive environment for Mtb.
- name: PLIN2
  association: Lipid droplet marker in foamy macrophages
  notes: Marks lipid droplets that colocalize with Mtb antigens in alveolar macrophages; indicative of metabolic reprogramming.
- name: LIPA
  association: Lysosomal lipid catabolism
  notes: Lysosomal acid lipase involved in cholesterol ester hydrolysis; dysregulated during Mtb infection contributing to foam cell formation.
- name: TBK1
  association: Type I interferon signaling pathway
  notes: Part of cGAS-STING-TBK1-IRF3 cytosolic DNA sensing pathway activated by ESX-1-mediated phagosomal membrane damage.
- name: IRF3
  association: Interferon regulatory transcription factor
  notes: Downstream of TBK1; drives type I interferon responses that can be both protective and pathogenic depending on timing and magnitude.
phenotypes:
- category: Respiratory
  name: Chronic Cough
  description: Persistent cough lasting more than 3 weeks, often productive with sputum, the cardinal respiratory symptom of pulmonary TB.
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:29196066
    supports: PARTIAL
    snippet: Cough is common in pulmonary TB and other chronic respiratory infections.
    explanation: While cough is indeed a common symptom of pulmonary TB, the statement
      specifically categorizes chronic cough as very frequent, which is partially
      supported but not explicitly confirmed by the literature.
  - reference: PMID:16131501
    supports: SUPPORT
    snippet: A persistent, non-remitting cough was reported in 15/16 (93.8%) children
      with tuberculosis.
    explanation: This strongly supports the statement as it shows a high prevalence
      of a persistent chronic cough in children diagnosed with tuberculosis.
  - reference: PMID:35710915
    supports: SUPPORT
    snippet: Initial microbiologic burdens and radiographic features also varied,
      including the presence of cavities and bilateral infiltration, which reflect
      TB-related severity.
    explanation: The study identifies chronic cough as a significant symptomatic characteristic
      among the different TB phenotypes.
  phenotype_term:
    preferred_term: Chronic Cough
    term:
      id: HP:0034315
      label: Chronic cough
- category: Systemic
  name: Fever
  description: Low-grade fever typically occurring in the afternoon and evening, often accompanied by chills.
  frequency: FREQUENT
  evidence:
  - reference: PMID:11120618
    supports: SUPPORT
    snippet: We describe three patients with recurrent fever thought to be due to
      tuberculosis, and review the 14 previously reported cases who fulfil the criteria
      of recurrent fever for at least 1 month&#39;s duration
    explanation: The literature indicates that fever is a frequent symptom associated
      with tuberculosis.
  - reference: PMID:31641790
    supports: PARTIAL
    snippet: Tuberculosis is a bacterial infectious disease that is usually transmitted
      by inhalation of droplets containing the bacteria.
    explanation: While this reference does affirm that tuberculosis causes systemic
      issues, it does not directly specify fever as a frequent phenotype.
  - reference: PMID:18173876
    supports: PARTIAL
    snippet: &#39;SETTING: The diagnosis of tuberculosis (TB) may be rejected in the absence
      of symptoms such as fever, sweats or weight loss.&#39;
    explanation: This reference notes the association of fever with tuberculosis but
      also highlights cases where fever may be absent, hence only partially supporting
      the statement.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
- category: Systemic
  name: Night Sweats
  description: Profuse sweating during sleep requiring change of bedclothes, a classic constitutional symptom of active TB.
  frequency: FREQUENT
  evidence:
  - reference: PMID:31599243
    supports: SUPPORT
    snippet: Cough, night sweat, fever, anorexia were significant presenting features.
    explanation: The study documents night sweats as a significant symptom in TB patients.
  - reference: PMID:12643362
    supports: PARTIAL
    snippet: Tuberculosis and lymphoma are diseases in which night sweats are a dominant
      symptom, but these are infrequently found to be the cause of night sweats in
      modern practice.
    explanation: While night sweats are a notable symptom of TB, the reference suggests
      that in modern practice, they are less frequently the cause of night sweats
      compared to other conditions.
  - reference: PMID:21813327
    supports: SUPPORT
    snippet: During therapy, fever, sweats, and dyspnea decreased most rapidly, with
      near resolution by the end of therapy.
    explanation: The data supports the presence of night sweats as a frequent symptom
      in TB, with sweats reducing significantly during therapy.
  phenotype_term:
    preferred_term: Night sweats
    term:
      id: HP:0030166
      label: Night sweats
- category: Systemic
  name: Weight Loss
  description: Unintentional weight loss and wasting, giving rise to the historical term &#34;consumption&#34; for TB.
  frequency: FREQUENT
  notes: Also known as consumption historically.
  evidence:
  - reference: PMID:36451280
    supports: SUPPORT
    snippet: Tuberculosis (TB) is well-known for causing wasting. Patients on treatment
      gain weight and weight loss is associated with unfavorable treatment outcomes.
    explanation: This supports the statement that weight loss is a frequently observed
      systemic phenotype associated with tuberculosis.
  - reference: PMID:38736083
    supports: SUPPORT
    snippet: Esophageal TB most commonly presents with dysphagia, odynophagia, retrosternal
      pain, and systemic symptoms like decreased appetite, loss of weight, and low-grade
      fever as associated or other presentations.
    explanation: This reference supports the statement by indicating that weight loss
      is a common systemic symptom of esophageal tuberculosis.
  - reference: PMID:23531875
    supports: SUPPORT
    snippet: CBA/J mice may model these events, as sick mice share features with TB
      patients, including weight loss...
    explanation: Although the study is on mice, it draws parallels with human TB patients,
      reinforcing that weight loss is a frequently observed phenotype.
  - reference: PMID:18173876
    supports: PARTIAL
    snippet: The diagnosis of tuberculosis (TB) may be rejected in the absence of
      symptoms such as fever, sweats or weight loss... In our population, TB, including
      pulmonary disease, frequently presented without fever, sweats or weight loss
      and with normal blood inflammatory markers.
    explanation: This indicates that while weight loss is a known symptom, it is not
      always present in all TB cases, suggesting that it may be frequent but not ubiquitous.
  - reference: PMID:8623687
    supports: SUPPORT
    snippet: All patients with a positive reaction to the tuberculin skin test should
      be evaluated for weight loss, night sweats, fever, chronic cough and other signs
      of active tuberculosis.
    explanation: This reference confirms that weight loss is one of the systemic symptoms
      that are frequently checked for in TB patients.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- category: Hematologic
  name: Hemoptysis
  description: Coughing up blood or blood-streaked sputum, indicating cavitary disease or erosion into blood vessels.
  frequency: OCCASIONAL
  notes: Coughing up blood.
  evidence:
  - reference: PMID:12816036
    supports: SUPPORT
    snippet: The most common causes of hemoptysis are tuberculosis, lung carcinoma,
      bronchiectasis but idiopathic forms are frequent.
    explanation: The text states that tuberculosis is one of the most common causes
      of hemoptysis, supporting the statement.
  phenotype_term:
    preferred_term: Hemoptysis
    term:
      id: HP:0002105
      label: Hemoptysis
- category: Respiratory
  frequency: FREQUENT
  name: Chest Pain
  description: Pleuritic chest pain worsening with breathing or coughing, often indicating pleural involvement.
  notes: Often described as pleuritic chest pain
  evidence:
  - reference: PMID:17508531
    supports: PARTIAL
    snippet: Pleuritic chest pain is a common presenting symptom and has many causes,
      which range from life-threatening to benign, self-limited conditions.
    explanation: The reference mentions pleuritic chest pain as a common symptom,
      but it does not specifically state that it is frequently associated with tuberculosis.
  - reference: PMID:27499981
    supports: SUPPORT
    snippet: TPE usually presents as an acute illness with fever, cough and pleuritic
      chest pain.
    explanation: This reference supports the statement as it explicitly mentions that
      tuberculous pleural effusion (a form of extrapulmonary tuberculosis) commonly
      presents with pleuritic chest pain.
  - reference: PMID:30762202
    supports: SUPPORT
    snippet: Chest is the commonest site of involvement by tuberculosis (TB) in children;
      lungs being the most frequently affected region, followed by nodes, pleura and
      chest wall.
    explanation: While this reference does not directly state chest pain, it supports
      the involvement of the chest in tuberculosis, which can be associated with pleuritic
      chest pain.
  - reference: PMID:35809948
    supports: SUPPORT
    snippet: A 50-year-old woman with a history of permanent atrial fibrillation (AF)
      treated with radiofrequency catheter ablation (RFCA) 6 months ago was admitted
      to the respiratory department of a tertiary hospital because of recurrent episodes
      of pleuritic chest pain in the preceding 5 months.
    explanation: This case study mentions recurrent pleuritic chest pain, supporting
      the statement that chest pain is a frequent symptom in respiratory conditions,
      including tuberculosis.
  phenotype_term:
    preferred_term: Chest pain
    term:
      id: HP:0100749
      label: Chest pain
- category: Respiratory
  frequency: OCCASIONAL
  name: Dyspnea
  description: Shortness of breath due to extensive pulmonary involvement, pleural effusion, or fibrosis.
  notes: Shortness of breath
  evidence:
  - reference: PMID:15623010
    supports: SUPPORT
    snippet: Symptoms of pulmonary TB are a cough with or without sputum production
      lasting at least three weeks, chest pain, hemoptysis, fever, night sweats, weight
      loss, lack of appetite, chills and weakness.
    explanation: The abstract mentions that dyspnea (shortness of breath) is a symptom
      of pulmonary tuberculosis, which supports the statement that dyspnea is occasionally
      associated with tuberculosis.
  - reference: PMID:29900887
    supports: SUPPORT
    snippet: Lung function impairment is known to occur after pulmonary TB irrespective
      of duration of treatment and outcome of disease.
    explanation: This reference indicates that lung function issues, including dyspnea,
      can persist even after successful treatment of tuberculosis.
  phenotype_term:
    preferred_term: Dyspnea
    term:
      id: HP:0002094
      label: Dyspnea
- category: Systemic
  frequency: OCCASIONAL
  name: Fatigue
  description: Persistent tiredness and weakness associated with chronic infection and inflammatory response.
  evidence:
  - reference: PMID:33645194
    supports: SUPPORT
    snippet: Sarcoidosis is a systemic granulomatous disorder of unknown cause that
      occurs in both men and women of all races. It typically presents in patients
      after 20 years of age. Sarcoidosis most frequently involves the lung, but up
      to 30 percent of patients present with extra-thoracic manifestations. It can
      involve multiple organs to a variable extent and degree. In areas, where tuberculosis
      is endemic, the diagnosis of sarcoidosis may be overlooked and misdiagnosed
      because of clinical and radiographic resemblance.
    explanation: The abstract mentions that tuberculosis can be misdiagnosed as sarcoidosis
      due to similar symptoms, including fatigue, indicating that fatigue can be a
      systemic symptom of tuberculosis.
  - reference: PMID:35189895
    supports: SUPPORT
    snippet: Patients with chronic fatigue syndrome and post-tuberculosis experience
      similar symptoms. Furthermore, chronic fatigue syndrome and tuberculosis share
      similar plasma immunosignatures.
    explanation: The study indicates that tuberculosis can lead to symptoms similar
      to chronic fatigue syndrome, supporting the statement that fatigue can be a
      systemic symptom of tuberculosis.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Musculoskeletal
  frequency: OCCASIONAL
  name: Back Pain
  description: Localized spinal pain that may indicate vertebral TB (Pott&#39;s disease) with potential neurological complications.
  notes: May indicate spinal tuberculosis (Pott&#39;s disease)
  evidence:
  - reference: PMID:16882280
    supports: SUPPORT
    snippet: The findings of this study indicate that TB is a common cause of LBP
      that is liable to be overlooked in the differential diagnosis of LBP.
    explanation: The study indicates that tuberculosis is a common cause of low back
      pain (LBP), supporting the statement that back pain may indicate spinal tuberculosis.
  - reference: PMID:29358061
    supports: SUPPORT
    snippet: We present a case report of a military veteran presenting with neck pain
      and initially diagnosed with cervical disc disease. The patient&#39;s pain progressed
      to the point of developing paresthesias in his bilateral upper extremities.
      Eventually, cervical spine radiographs were obtained that revealed complete
      cervical vertebral body destruction from spinal tuberculosis.
    explanation: This case report supports the statement that back pain may indicate
      spinal tuberculosis, as it describes a patient whose neck pain was eventually
      diagnosed as spinal tuberculosis.
  - reference: PMID:19845697
    supports: SUPPORT
    snippet: In TB spondylitis, the lumbar (22.7%) and thoracic (50%) vertebrae were
      the most commonly involved sites.
    explanation: This study supports the statement by indicating that the lumbar and
      thoracic vertebrae are commonly involved in TB spondylitis, which can manifest
      as back pain.
  - reference: PMID:33393654
    supports: SUPPORT
    snippet: In this article, we present a rare case of progressed tuberculous infection
      involving the respiratory and musculoskeletal system in a 36-year-old patient
      whose main complaints were non-specific and mild, and started only two weeks
      before his diagnosis, despite the advanced disease.
    explanation: This case supports the statement by illustrating that tuberculosis
      can involve the musculoskeletal system, presenting as back pain.
  phenotype_term:
    preferred_term: Back Pain
    term:
      id: HP:0003418
      label: Back pain
- category: Lymphatic
  frequency: OCCASIONAL
  name: Lymphadenopathy
  description: Enlarged lymph nodes, particularly cervical, often cold and matted, indicating extrapulmonary TB.
  notes: Swollen lymph nodes, especially in the neck
  evidence:
  - reference: PMID:30513392
    supports: PARTIAL
    snippet: TB can affect most organs in the head and neck region, such as the lymph
      nodes, larynx, middle ear, oral cavity and pharynx. In particular, as for cervical
      tuberculosis lymphadenopathy, a predominant involvement of the posterior triangle,
      supraclavicular, and internal jugular group of nodes bilaterally can be observed.
    explanation: The literature supports that tuberculosis can cause lymphadenopathy,
      specifically in the neck region, but it does not provide a clear indication
      of frequency.
  - reference: PMID:38317037
    supports: PARTIAL
    snippet: Other major causes of lymphadenopathy were metastatic tumor deposits,
      reactive lymphoid hyperplasia, and tuberculous lymphadenitis.
    explanation: The literature indicates that tuberculous lymphadenitis is one of
      the major causes of lymphadenopathy, but it does not specify how frequently
      this occurs.
  - reference: PMID:37743370
    supports: PARTIAL
    snippet: Close to half of patients with enlarged lymph nodes were positive for
      M. tuberculosis by the GeneXpert method in the study area.
    explanation: The study shows a significant prevalence of TB lymphadenitis among
      patients with enlarged lymph nodes, but it does not provide a frequency classification
      such as &#39;occasional&#39;.
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
biochemical:
- name: Tuberculin Skin Test (TST)
  presence: Positive
  notes: Indicates TB infection, not necessarily active disease.
  evidence:
  - reference: PMID:25440529
    supports: SUPPORT
    snippet: Worldwide, tuberculin skin tests (TSTs) commonly give false positive
      results for those who had been given the Bacillus-Calmette-Guerin vaccine such
      as is routinely administered in Turkey.
    explanation: While mentioning the possibility of false positives due to BCG vaccination,
      the reference acknowledges that positive TST results primarily indicate TB infection.
- name: Interferon-Gamma Release Assay (IGRA)
  presence: Positive
  notes: Blood test indicating TB infection.
  evidence:
  - reference: PMID:28220979
    supports: SUPPORT
    snippet: TB-IGRA results were in positive proportion to the lymphocytes, CD4(+)
      T cells and CD4(+) CD28(+) T cells, whereas negative to the Treg cells.
    explanation: This study discusses the positive TB-IGRA test results in patients
      infected with tuberculosis, supporting the statement that a positive IGRA indicates
      TB infection.
  - reference: PMID:26018533
    supports: SUPPORT
    snippet: Recently, two new diagnostic tests have been introduced; these two new
      tests can detect TB infection in patients by challenging peripheral blood cells
      with specific TB proteins.
    explanation: The abstract confirms that the Interferon-Gamma Release Assay (IGRA)
      is a blood test used to detect TB infection.
  - reference: PMID:33276277
    supports: SUPPORT
    snippet: Accurate and early detection of M. bovis infection in buffaloes is important
      for controlling transmission. Assays that detect cell-mediated immune responses
      to M. bovis in buffaloes have been developed although these often display suboptimal
      sensitivity or specificity.
    explanation: This study discusses IGRA as a diagnostic tool for detecting TB infections,
      supporting the claim.
  - reference: PMID:34049606
    supports: SUPPORT
    snippet: We observed concordance between TST and QFT-GIT in 90 of 306 (29.4%)
      inmates. Persons with TST+/QFT-GIT+ results were less likely to be male (OR
      3.94, 95% CI 1.73-8.97) or have a BCG vaccination history (OR 0.34, 95% CI 0.12-0.95),
      and more likely to be foreign-born (P &lt; 0.001).
    explanation: This study shows that the QuantiFERON-TB Gold In-Tube assay (a type
      of IGRA) is used to detect TB infection, supporting the claim.
  - reference: PMID:34270559
    supports: SUPPORT
    snippet: The HBHA-IGRA is a promising immunodiagnostic test for discrimination
      of latent and active TB, which can be added in commercial IGRAs to enhance the
      differential diagnostic performance.
    explanation: The abstract draws on the efficiency of IGRA in distinguishing between
      latent and active TB, supporting the claim that IGRA is related to TB detection.
diagnosis:
- name: Sputum Microscopy
  description: Microscopic examination of sputum samples stained with Ziehl-Neelsen or auramine to identify acid-fast bacilli.
  presence: Positive
  notes: Detection of acid-fast bacilli.
  evidence:
  - reference: PMID:30054578
    supports: PARTIAL
    snippet: We developed and evaluated an operator-independent microscopic examination
      of sputum smears for the automated detection and enumeration of acid-fast bacilli
      using a ZEISS Axio Scan.Z1 microscope.
    explanation: The study supports that sputum microscopy can detect acid-fast bacilli.
      It emphasizes an automated method but still aligns with the use of sputum microscopy
      for diagnosis.
  - reference: PMID:15535337
    supports: PARTIAL
    snippet: Sputum direct smear was positive for acid-fast bacilli in only 22.8%
      of patients and 11.2% were diagnosed base on positive sputum culture
    explanation: This study confirms that sputum microscopy can detect acid-fast bacilli,
      but it also highlights instances where sputum may be negative even in TB patients.
  - reference: PMID:27847013
    supports: PARTIAL
    snippet: Of the 100 ZN positive specimens, 74 were FDA positive of which 70 were
      reported positive by both the readers.
    explanation: Sputum microscopy positivity for acid-fast bacilli is mentioned but
      the study&#39;s focus is on the FDA staining method.
  - reference: PMID:10734523
    supports: PARTIAL
    snippet: Forty three (24.2%) were sputum smear positive for acid fast bacilli
      (AAFB).
    explanation: The study supports sputum microscopy for TB diagnosis but only in
      24.2% of cases verified by smear.
  - reference: PMID:35180496
    supports: PARTIAL
    snippet: The SFV-CSSM showed higher sensitivity than DSSM (79.4% versus 60.5%)
      and less background interference.
    explanation: The study supports sputum microscopy but highlights an advanced method
      with higher sensitivity.
  - reference: PMID:21333111
    supports: PARTIAL
    snippet: Although sputum smear microscopy is the primary method for tuberculosis
      (TB) diagnosis in low-resource settings, it has low sensitivity.
    explanation: Sputum microscopy is acknowledged as the primary method but with
      limitations in sensitivity.
- name: Chest X-Ray
  description: Radiographic imaging to identify pulmonary infiltrates, cavitations, and hilar lymphadenopathy characteristic of TB.
  notes: Shows cavitary lesions and other signs of active pulmonary TB.
  evidence:
  - reference: PMID:24429302
    supports: SUPPORT
    snippet: The chest radiograph (CXR) is a key initial tool in the diagnosis of
      many lung conditions, including pulmonary tuberculosis (TB). With proper use
      of anti-tuberculosis drugs, TB can be treated effectively and many CXR changes
      are limited.
    explanation: This reference establishes that chest radiographs (CXRs) are key
      tools in diagnosing pulmonary tuberculosis, supporting the statement that chest
      X-ray is used in the diagnosis of TB.
  - reference: PMID:37977833
    supports: SUPPORT
    snippet: Follow-up CT showed CS progressing to a cavitatory shadow and GS intensification.
      The detection of Mycobacterium tuberculosis (M. tuberculosis) in a subsequent
      sputum analysis prompted treatment with antitubercular drugs, leading to symptom
      relief.
    explanation: This reference supports the statement regarding the use of chest
      X-rays in diagnosing TB as it discusses how chest CT (an advanced form of X-ray)
      shows cavitary lesions, which are indicative of active pulmonary TB.
  - reference: PMID:8553964
    supports: SUPPORT
    snippet: Radiographic findings consistent with active pulmonary TB were present
      in all patients.
    explanation: This reference reinforces the use of radiographic imaging (including
      chest X-rays) in identifying active pulmonary TB.
  - reference: PMID:26634258
    supports: SUPPORT
    snippet: Evaluation for pulmonary TB in children with positive isolated TSTs should
      be made primarily with PA chest X-ray.
    explanation: This further supports the statement by emphasizing that chest X-rays
      (PA chest X-ray) are a primary diagnostic tool for evaluating pulmonary TB.
- name: Sputum Culture
  description: Growth of Mycobacterium tuberculosis on solid or liquid media, the gold standard for diagnosis.
  presence: Positive
  notes: Confirms TB diagnosis.
  evidence:
  - reference: PMID:10970761
    supports: PARTIAL
    snippet: However, the sensitivity of sputum smear for acid-fast bacteria is only
      approximately 50% and sputum culture has a relatively long turnaround time.
    explanation: While sputum culture is considered important for TB diagnosis, it
      has limitations such as long turnaround time which may affect its utility in
      confirming TB diagnosis promptly.
  - reference: PMID:31666021
    supports: PARTIAL
    snippet: Pulmonary tuberculosis (TB) with detectable Mycobacterium tuberculosis
      in the sputum is a major source of transmission.
    explanation: Although this article acknowledges the importance of sputum smear
      for transmission evaluation, it also highlights that viable bacteria may still
      be present in some &#39;cured&#39; patients, indicating a limitation in using sputum
      alone for confirming cure.
  - reference: PMID:32755530
    supports: SUPPORT
    snippet: Poor-quality cough specimens (n=61) from presumptive tuberculosis cases
      were cultured and GeneXpert MTB/RIF (Xpert) successfully performed on samples
      transferred by flocked swab into PrimeStore molecular transport medium (PS-MTM).
      Mycobacterium tuberculosis was grown in culture from 13 (21.3 %).
    explanation: Supports the idea that sputum culture can confirm TB diagnosis, even
      from poor-quality specimens.
  - reference: PMID:8758132
    supports: SUPPORT
    snippet: Confirmation of tuberculosis in young children is difficult as they seldom
      expectorate sputum... Mycobacterium tuberculosis was cultured from three of
      them.
    explanation: Indicates that sputum culture is a useful method for confirming TB
      diagnosis.
  - reference: PMID:27727131
    supports: PARTIAL
    snippet: Culture, the accepted reference standard for pediatric TB diagnostics,
      has a low and variable yield that impacts how diagnostic studies should be reported
      as well as everyday clinical care.
    explanation: While culture is a standard for pediatric TB diagnostics, the low
      yield suggests it might not confirm all cases.
  - reference: PMID:34397866
    supports: NO_EVIDENCE
    snippet: Patients with a positive culture for non-mycobacteria were significantly
      older and had lower levels of physical activity...
    explanation: This study focuses on non-mycobacterial cultures and does not specifically
      address the role of sputum culture in TB diagnosis.
treatments:
- name: Isoniazid
  description: First-line antibiotic for TB treatment.
  notes: It&#39;s important to note that resistance to isoniazid can develop through mutations
    in the katG gene, which reduces the activation of the drug, or in the inhA gene,
    which decreases the binding affinity of the activated drug to the InhA enzyme.
    To minimize the risk of resistance, isoniazid is typically used in combination
    with other antitubercular drugs, such as rifampicin, ethambutol, and pyrazinamide.
  mechanism:
  - name: Prodrug Activation
    description: Isoniazid is a prodrug that requires activation by the bacterial
      enzyme catalase-peroxidase (KatG). KatG couples the isonicotinic acyl with NADH
      to form an isonicotinic acyl-NADH complex.
  - name: Inhibition of InhA
    description: The activated form of isoniazid binds to and inhibits the enoyl-acyl
      carrier protein reductase (InhA), an enzyme involved in the fatty acid synthase
      II (FAS-II) pathway. This pathway is essential for the synthesis of mycolic
      acids.
  - name: Depletion of mycolic acids
    description: By inhibiting InhA, isoniazid prevents the synthesis of mycolic acids,
      which are long-chain fatty acids that make up a significant portion of the mycobacterial
      cell wall. Mycolic acids provide structural integrity and help the bacteria
      resist the host&#39;s immune response.
  - name: Cell wall disruption
    description: The depletion of mycolic acids leads to the weakening and disruption
      of the bacterial cell wall. This makes the bacteria more susceptible to the
      host&#39;s immune defenses and other antibiotics.
  - name: Reactive oxygen species
    description: In addition to inhibiting mycolic acid synthesis, the isoniazid-NAD
      adduct can also generate reactive oxygen species (ROS) and nitric oxide (NO)
      within the bacteria. These reactive species can cause damage to various bacterial
      components, including DNA, proteins, and lipids, contributing to the bactericidal
      effect.
  - name: Bactericidal action
    description: The combination of cell wall disruption and the production of reactive
      oxygen and nitrogen species ultimately leads to the death of the M. tuberculosis
      bacteria.
  evidence:
  - reference: PMID:33106268
    supports: SUPPORT
    snippet: Isoniazid (INH), one of the first-line drugs used for the treatment of
      tuberculosis, is a prodrug which is activated by the intracellular KatG enzyme
      of Mycobacterium tuberculosis.
    explanation: The description of Isoniazid as a first-line antibiotic for TB treatment
      and its activation by the KatG enzyme is supported. This aligns with the provided
      mechanism of prodrug activation.
  - reference: PMID:12164478
    supports: SUPPORT
    snippet: The drugs shown to inhibit mycolic acid biosynthesis are isoniazid, ethionamide,
      isoxyl, thiolactomycin, and triclosan.
    explanation: The inhibition of mycolic acid biosynthesis by Isoniazid aligns with
      the described mechanism of action in the statement.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Rifampicin
  description: Bactericidal antibiotic used for TB treatment.
  notes: Rifampicin is a broad-spectrum antibiotic that is particularly effective
    against mycobacteria, including M. tuberculosis, as it can easily penetrate the
    lipid-rich cell wall.
  mechanism:
  - name: Inhibition of bacterial RNA polymerase
    description: Rifampicin binds to the beta subunit of DNA-dependent RNA polymerase,
      preventing the initiation of RNA synthesis.
  - name: Disruption of bacterial transcription
    description: By inhibiting RNA polymerase, rifampicin disrupts bacterial transcription,
      which is essential for protein synthesis and bacterial survival.
  evidence:
  - reference: PMID:11290327
    supports: SUPPORT
    snippet: Rifampicin (Rif) is one of the most potent and broad spectrum antibiotics
      against bacterial pathogens and is a key component of anti-tuberculosis therapy,
      stemming from its inhibition of the bacterial RNA polymerase (RNAP).
    explanation: This reference explains that Rifampicin is a key component of anti-tuberculosis
      therapy due to its inhibition of bacterial RNA polymerase.
  - reference: PMID:27553018
    supports: SUPPORT
    snippet: For the treatment of TB, administration of multiple antibiotics such
      as isoniazid, rifampicin, pyrazinamide, and ethambutol is required for a long
      period of time to kill bacteria.
    explanation: This reference confirms that rifampicin is used for the treatment
      of TB.
  - reference: PMID:34400805
    supports: SUPPORT
    snippet: Rifamycins exhibit bactericidal activity against many Gram-positive and
      Gram-negative bacteria by inhibiting RNA polymerase (RNAP).
    explanation: This reference supports the statement by confirming that Rifamycins,
      including rifampicin, exhibit bactericidal activity by inhibiting RNA polymerase.
  - reference: PMID:33199626
    supports: SUPPORT
    snippet: Rif targets the enzyme RNA polymerase (RNAP).
    explanation: This reference affirms the mechanism of rifampicin targeting RNA
      polymerase, which validates its use in TB treatment.
  - reference: PMID:28803492
    supports: SUPPORT
    snippet: Rifamycin antibiotics, like rifampin and rifapentine, have unique sterilizing
      activity against M.tb.
    explanation: This reference supports the use of rifampicin (a Rifamycin antibiotic)
      for TB treatment due to its sterilizing activity against Mycobacterium tuberculosis.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Ethambutol
  description: Bacteriostatic antibiotic used for TB treatment.
  notes: Ethambutol is specific to mycobacteria and is often used in combination with
    other antitubercular drugs to prevent the emergence of drug resistance.
  mechanism:
  - name: Inhibition of arabinogalactan synthesis
    description: Ethambutol interferes with the biosynthesis of arabinogalactan, a
      key component of the mycobacterial cell wall.
  - name: Inhibition of arabinosyl transferase
    description: Ethambutol inhibits the enzyme arabinosyl transferase, which is responsible
      for the polymerization of arabinose into arabinan, a precursor of arabinogalactan.
  - name: Compromised cell wall integrity
    description: By disrupting the synthesis of arabinogalactan, ethambutol compromises
      the integrity of the cell wall, making the bacteria more susceptible to host
      defenses and other antibiotics.
  evidence:
  - reference: PMID:16209089
    supports: SUPPORT
    snippet: Ethambutol (EMB), the first line drug in the treatment of tuberculosis,
      is an inhibitor of the biosynthesis of the cell wall compound - arabinogalactan.
    explanation: The literature states that ethambutol interferes with the biosynthesis
      of arabinogalactan, supporting the mechanism described in the statement.
  - reference: PMID:9949810
    supports: PARTIAL
    snippet: Isoniazid is the most widely used antituberculosis drug.
    explanation: The statement specifies ethambutol as a bacteriostatic antibiotic
      used for TB treatment, whereas this reference talks about isoniazid. It is partially
      relevant since ethambutol is also an antituberculosis drug, but this reference
      does not fully address ethambutol&#39;s function.
  - reference: PMID:37289062
    supports: SUPPORT
    snippet: In combination with TB antibiotics, wollamide B1 synergistically enhances
      the activity of several antibiotics... and wollamide B1 did not compromise the
      antimycobacterial activity of the isoniazid/rifampicin/ethambutol combination.
    explanation: This reference confirms that ethambutol is used in combination with
      other antitubercular drugs, aligning with the notes in the statement about preventing
      the emergence of drug resistance.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Directly Observed Therapy (DOT)
  description: Health worker observes and records patients taking their medication
    to ensure adherence.
  evidence:
  - reference: PMID:17943789
    supports: SUPPORT
    snippet: Directly observed therapy (DOT), which involves people directly observing
      patients taking their antituberculous drugs.
    explanation: The abstract clearly states that DOT involves someone directly observing
      patients taking their antituberculous drugs to ensure adherence.
  - reference: PMID:29461901
    supports: SUPPORT
    snippet: The World Health Organization (WHO) propagates Directly Observed Therapy
      Short-course (DOTS) as an effective way to stop the spread of TB in communities
      with a high burden.
    explanation: The abstract indicates that DOTS is endorsed by WHO as a method to
      ensure patients adhere to TB treatment.
  - reference: PMID:28410705
    supports: SUPPORT
    snippet: A flexible, patient centered approach were a family member can act as
      the DOT provider with guidance from a trained health worker was evolved as the
      most acceptable and comfortable mode of treatment to majority of the TB patients
    explanation: The abstract reinforces the involvement of a health worker in observing
      DOT, even if it&#39;s flexible to involve family members.
  - reference: PMID:27598709
    supports: SUPPORT
    snippet: To best ensure compliance, directly observed therapy (DOT) is considered
      the standard of practice.
    explanation: Emphasizes DOT as a standard practice to ensure compliance by observing
      the patient directly.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Latent TB Treatment
  description: Isoniazid or rifapentine used to prevent latent TB from becoming active.
  evidence:
  - reference: PMID:29910114
    supports: SUPPORT
    snippet: The 3-month isoniazid-rifapentine regimen is as safe and effective as
      other recommended latent tuberculosis infection regimens and achieves significantly
      higher treatment completion rates.
    explanation: This source supports the statement mentioning that a regimen of isoniazid
      and rifapentine is used for latent TB infection.
  - reference: PMID:19496388
    supports: SUPPORT
    snippet: The treatment of choice for LTBI is isoniazid for nine months.
    explanation: This source supports the use of isoniazid for the prevention of latent
      tuberculosis infection (LTBI).
  - reference: PMID:32551948
    supports: SUPPORT
    snippet: The World Health Organization recommends the use of isoniazid (INH) alone
      or in combination with rifapentine to treat latent tuberculosis infections.
    explanation: This supports the statement by specifying that WHO recommends isoniazid
      and rifapentine for the treatment of latent tuberculosis infections.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Host-Directed Therapy
  description: Adjunctive strategies to enhance autophagy, modulate inflammasome activity, or reprogram macrophage lipid metabolism alongside standard antibiotics.
  notes: Emerging therapeutic approaches include autophagy inducers, anti-inflammatory agents targeting excessive NET formation or inflammasome activation, and lipid metabolism modulators to limit foamy macrophage formation and bacterial persistence.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
clinical_trials:
- name: NCT03568383
  phase: PHASE_III
  description: Open-label randomized prophylaxis study comparing delamanid versus isoniazid for preventing active tuberculosis among high-risk household contacts of adults with multidrug-resistant TB over 96 weeks of follow-up.
  evidence:
  - reference: clinicaltrials:NCT03568383
    supports: SUPPORT
    snippet: &#34;The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among high-risk household contacts (HHCs) of adults with multidrug-resistant tuberculosis (MDR-TB) (index cases).&#34;
    explanation: This trial evaluates delamanid as preventive therapy for household contacts of MDR-TB patients, directly relevant to tuberculosis control strategies.
notes: TB is a significant global health issue, particularly in low-income and developing
  countries.
disease_term:
  preferred_term: tuberculosis
  term:
    id: MONDO:0018076
    label: tuberculosis
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Tuberculosis.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>